Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment

Who May Qualify: - \* Willingness to provide written willing to sign a consent form before any study-specific procedures or activities are performed - Age ≥ 18 years of age, at the time of consent - Documented, diagnosed by tissue sample (biopsy-confirmed) diagnosis of multiple myeloma (MM), diffuse large B cell lymphoma (DLBCL),follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), or small lymphocytic lymphoma (SLL), or primary mediastinal B cell lymphoma (PMBL). All number of prior lines of therapy are allowed - History of prior vaccination against common VPD - Approved by managing physician for CAR-T therapy, with preparative conditioning planned within the next 90 days - Approved by managing physician for revaccination against Streptococcus pneumoniae or tetanus Who Should NOT Join This Trial: - \* Ongoing use of immunosuppressive agents or plans for immunosuppressive therapy that would interfere with interpretation of study endpoints - Uncontrolled, intercurrent illness including, but not limited to, systemic infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements or make the study procedures unadvisable Always talk to your doctor about whether this trial is right for you.